REGENXBIO (RGNX) Stock Price, News & Analysis

Company Overview

REGENXBIO Inc. (NASDAQ: RGNX) is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases. The company’s programs use adeno-associated virus (AAV) vectors to deliver genetic material to targeted cells, with the goal of addressing the underlying causes of disease rather than primarily treating symptoms.

REGENXBIO’s technology is built around its NAV AAV Technology Platform, which supports the design and development of gene-delivery vectors. Its pipeline has included investigational therapies for conditions such as Duchenne muscular dystrophy, Hunter syndrome, age-related macular degeneration and other rare diseases. The company also pursues licensing and collaboration arrangements that allow other biotechnology and pharmaceutical companies to use its AAV technology.

Founded in 2009, REGENXBIO is headquartered in Rockville, Maryland, and conducts research and development activities through collaborations and clinical programs in the United States and other regions where its studies and regulatory activities are conducted. The company is led by Kenneth T. Mills, who serves as president and chief executive officer.

Key Stats

• Today's Range: $7.00 to $7.54
• 50-Day Range: $6.58 to $10.72
• 52-Week Range: $5.45 to $16.19
• Volume: 1.06 million shs
• Average Volume: 1.38 million shs
• Market Capitalization: $475.27 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.17
• Consensus Rating: Moderate Buy

REGENXBIO Stock Analysis - MarketRank™

REGENXBIO scored higher than 57% of companies evaluated by MarketBeat, and ranked 457th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

REGENXBIO has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 9 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

REGENXBIO has a consensus price target of $23.17, representing about 221.8% upside from its current price of $7.20.

Amount of Analyst Coverage

REGENXBIO has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for REGENXBIO are expected to grow in the coming year, from ($3.70) to ($2.94) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of REGENXBIO is -1.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of REGENXBIO is -1.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

REGENXBIO has a P/B Ratio of 3.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.74% of the float of REGENXBIO has been sold short.

Short Interest Ratio / Days to Cover

REGENXBIO has a short interest ratio ("days to cover") of 6.78.

Change versus previous month

Short interest in REGENXBIO has recently increased by 4.52%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

REGENXBIO does not currently pay a dividend.

Dividend Growth

REGENXBIO does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.71

News Sentiment

REGENXBIO has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for REGENXBIO this week, compared to 7 articles on an average week.

Search Interest

Only 2 people have searched for RGNX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

4 people have added REGENXBIO to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, REGENXBIO insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.22% of the stock of REGENXBIO is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

88.08% of the stock of REGENXBIO is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 11/01/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RGNX
• CIK: 1590877
• Web: www.regenxbio.com
• Phone: (240) 552-8181
• Fax: N/A
• Employees: 371
• Year Founded: 2009

Price Target and Rating

• Average Price Target for REGENXBIO: $23.17
• High Price Target: $50.00
• Low Price Target: $12.00
• Potential Upside/Downside: +221.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.79)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$193.88 million
• Net Margins: -112.58%
• Pretax Margin: -112.58%
• Return on Equity: -220.07%
• Return on Assets: -46.04%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.86
• Quick Ratio: 2.86

Sales & Book Value

• Annual Sales: $170.44 million
• Price / Sales: 2.79
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.03 per share
• Price / Book: 3.55

Miscellaneous

• Outstanding Shares: 66,010,000
• Free Float: 56,626,000
• Market Cap: $475.27 million
• Optionable: Optionable
• Beta: 1.13